Dory Pharmaceuticals: Wang Qingtai and Cao Xiaobing's tender offer has expired, and the company's stock will resume trading on February 27, 2026.

Duorui Medicine announced that the company's stock will resume trading on February 27, 2026. During the tender offer period from January 22, 2026 to February 24, 2026, Wang Qingtai had 3 pre-accepted shareholder accounts with a total of 17.6 million shares pre-accepted, while Cao Xiaobing had 4 pre-accepted shareholder accounts with a total of 1.85 million shares pre-accepted. After the completion of this tender offer, the acquirer and its concerted actors will hold a total of 43.12 million shares of Duorui Medicine, accounting for 53.90% of the total share capital of the company.